Back

ARF4-mediated Retrograde Trafficking Drives Chemoresistance in Glioblastoma

Budhiraja, S.; Baisiwala, S.; Perrault, E.; Cho, S.; Nandoliya, K.; Dara, G.; Zolp, A.; Chen, L.; Dmello, C.; Park, C.; Sonabend, A.; Ahmed, A.

2021-07-19 cancer biology
10.1101/2021.07.18.451328 bioRxiv
Show abstract

Glioblastoma (GBM) is the most common type of adult malignant brain tumor, with a median survival of only 21 months. This is partly due to the high rate of resistance to conventional therapy, including temozolomide (TMZ), leading to recurrence rates close to 100%. It still remains unknown what drives the development of this resistance. To identify the unknown genes driving the development of this resistance, we performed a genome-wide CRISPR knockout screen comparing a DMSO-treated population with a TMZ-treated population over 14 days. We identified 4 previously unstudied genes - ARF4, PLAA, SPTLC1, and PIGK - that showed significant elevations in expression in recurrent tumors in patient datasets, along with significant survival benefits corresponding to low gene expression. Further investigation of ARF4, known to be involved in retrograde trafficking, allowed us to identify a mechanism of resistance that is mediated by increased retrograde transport of EGFR into the nucleus. Ultimately, our CRISPR-Cas9 screen has identified a promising therapeutic target, ARF4, which may drive GBMs high resistance to chemotherapy.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.